Einführung der vertraulichen Erstattungspreise für Medikamente

This procedure concerns a written question about the introduction of confidential reimbursement prices for medicines. It seeks clarification on the implications and potential benefits of such a system. The question likely affects pharmaceutical companies, healthcare providers, and potentially patients by influencing drug pricing and accessibility.